DS Biopharma, headquartered in Dublin, Ireland, and focused on therapies for inflammatory and fibrotic skin and pulmonary disorders, recently announced that a Phase 1 clinical trial evaluating safety and dosing levels for its drug candidate DS102 (15-HEPE) has been successfully completed. DS102 is an oral bioactive lipid drug developed as…
Potential Therapy for IPF and Fatty Liver Disorders Shows Safety in Early Clinical Trial
“This is John’s story. A true story. A day by day account of his life as told by himself in a series called – Emphysema Man. Proof positive that, with the exception of death and taxes, there are no guarantees in life.” Learn more about Emphysema: https://bit.ly/1ONmRdG…
Read the articles: 1. Idiopathic Pulmonary Fibrosis Trial to Test Combination of Existing Treatments 2. IPF Study Focuses on Patient and Caregiver Needs Beyond Treatment 3. IPF Patients Seen to Benefit from Pirfenidone Treatment…
“David Flurett was diagnosed with IPF – an incurable disease that causes scarring of the lungs. His doctors put him on a lung transplant list. On May 18, 2014 he received a lung transplant at MUSC.” Read more about Pulmonary Fibrosis: https://bit.ly/1lfMsiZ Learn more about Lung Transplants: https://bit.ly/1SNRT3u…
https://www.youtube.com/watch?v=FrPNIFjLgRw “Dr Toby Maher of the Royal Brompton Hospital, UK, talks about the impact of idiopathic pulmonary fibrosis (IPF) and the need to shed light on this ‘invisible disease’ .” Learn more about IPF:Â https://bit.ly/1QiRmr3…
A potentially important new study, published in the Journal of Biological Chemistry, identified fibroblast activation protein (FAP) as a crucial factor in collagen fragment clearance in the lungs. Clearing collagen fragments is a key step in reducing tissue scarring and restoring lung function following injury, making FAP an interesting target…
New data from Phase 3 clinical studies of Genentech’s Esbriet (pirfenidone), a drug developed for the treatment of pulmonary fibrosis (PF), showed the treatment’s efficacy over time. The data presentation, the “Effect of continued treatment with pirfenidone following a clinically meaningful decline in percent predicted forced vital capacity…
“Donald used his own adult stem cells to treat his COPD. He was dealing with cardiologists and pulmonologists, but he just couldn’t see himself getting any better until he tried the stem cell treatment.” Learn more about Stem Cells: https://bit.ly/1Tw7AMJ…
The University of Cincinnati (UC) Medical Center is among the 19 medical centers recently invited after careful review to become part of the Pulmonary Fibrosis Foundation (PFF) Care Center Network. The network now comprises 40 centers across 26 U.S. states with established expertise in the treatment of pulmonary fibrosis…
PRM-151 is a recombinant human serum amyloid P/pentraxin 2 protein developed by Promedior, a biotechnology company developing therapies for fibrotic diseases using plasma-derived proteins and peptides. Also referred to as PTX2, the therapy is injected intravenously in patients and is showing promise as an effective anti-fibrotic agent which can be used to target several…
